2004
DOI: 10.1016/s1542-3565(03)00318-5
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
43
1

Year Published

2004
2004
2009
2009

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 41 publications
(46 citation statements)
references
References 29 publications
2
43
1
Order By: Relevance
“…Nimesulide, 71 celecoxib, 62 rofecoxib, 75 and lumiracoxib 74 do not increase small intestinal permeability when taken short term.…”
Section: Cox-2 Selective Agentsmentioning
confidence: 93%
See 1 more Smart Citation
“…Nimesulide, 71 celecoxib, 62 rofecoxib, 75 and lumiracoxib 74 do not increase small intestinal permeability when taken short term.…”
Section: Cox-2 Selective Agentsmentioning
confidence: 93%
“…73 Lumiracoxib, which is classifi ed as a COX-2 selective agent (coxib), despite resembling diclofenac and inhibiting gastric COX-1 signifi cantly is purported not to increase intestinal permeability even though it has a low pKa. 74 What is of interest is that these short-term permeability studies can be translated to long-term usage in most cases. Hence the same drugs that increase intestinal permeability in the short term are also associated with increased permeability when given long term.…”
Section: Small Intestinal Permeability In Humansmentioning
confidence: 99%
“…The lack of intestinal damage with this class of drugs in animal experiments [24, 39, 40] has been confirmed in clinical studies [23,41,42,43]. Most patients taking either meloxicam [27] or nimesulide [44], two preferential COX-2 inhibitors, had normal intestinal permeability and no increase in intestinal inflammation in comparison to control patients not taking the drug.…”
Section: Lesions Induced By Nsaids In the Distal Gi Tractmentioning
confidence: 94%
“…18 Endoscopic studies in volunteers and patients have shown a reduced effect on acute GI injury, prostaglandin synthesis and medium-term development of ulcers compared with ibuprofen 19,20 and naproxen. 21,22 We set up the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) in order to evaluate directly whether lumiracoxib would reduce the incidence of ulcer complications over 52 weeks in patients with OA. Whilst this is now a necessary part of the evaluation for registration of any COX-2 selective inhibitor in the USA, it is of particular interest for lumiracoxib, given its structurally distinct nature.…”
mentioning
confidence: 99%